This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Metastatic Pancreatic Cancer
and you are
between 18 and 75
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purpose of the study is to determine whether ODSH (2-0,3-0 desulfated heparin), a low anticoagulant heparin derivate with preserved anti-inflammatory and anti-neoplastic characteristics is efficacious in patients with metastatic pancreatic cancer with gemcitabine and nab-paclitaxel ( Abraxane) as first line therapy.

Provided treatments

  • Drug: Abraxane ( Nab-paclitaxel)
  • Drug: Abraxane ( Nab-paclitaxel)
  • Drug: Gemcitabine
  • Drug: Gemcitabine
  • Drug: ODSH ( 2-O, 3-O Desulfated Heparin)
  • Drug: ODSH ( 2-O, 3-O Desulfated Heparin)
  • Drug: Abraxane ( nab-paclitaxel)
  • Drug: Gemcitabine

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01461915. The sponsor of the trial is Cantex Pharmaceuticals and it is looking for 61 volunteers for the current phase.
Official trial title:
A Randomized Phase II Open Label Study to Assess the Efficacy & Safety of Gemcitabine + Abraxane® With or Without ODSH (2-0, 3-0 Desulfated Heparin) as First Line Treatment of Metastatic Pancreatic Cancer